Scientific insights: Kidney disease
Is the kidney disease the next big therapeutic area?
Numerous biopharmas have approached Vibe Bio to use our AI, VibeOne, to help identify new kidney indications for them to pursue.
Why? Our insight: the momentum in this therapeutic area emerges as the FDA has approved new biomarkers for kidney-related indications. The prospect of lower development costs and faster trials entices many.
Given the volume of interest, I thought we’d share an overview. We used VibeOne to investigate indications and help stratify them based on a customizable strategy rubric. Our AI computed multiple complex factors for each indication to help prioritize them, including:
- 💉 Unmet Medical Need
- 🤕 Patient Population
- 🧬 Scientific Feasibility
- 📋 Regulatory Pathway
- 🥇 Competitive Landscape
among others…
We could add other criteria, like genetics or modality fit, but kept it simple initially. IMHO, there’s several hidden gem indications that seem ripe for new development programs.
One that caught my eye was Polycystic Kidney Disease (PKD). PKD is a condition that affects up to 600,000 patients in the US. Current treatments, like JYNARQUE™ (tolvaptan) from Otsuka America Pharmaceutical, Inc., leave much to be desired for patients and motivate the development of new therapies.
…not surprisingly, VibeOne found 100+ in development for this disease alone globally!
Picking the right indication is a complex, interdisciplinary decision. Many factors need to be considered to find the diseases that your company is best positioned to solve.
If you want to see our prioritized list of kidney indications or our strategy rubric, reach out—we’d be happy to share the details.
